- Home
- UNCY vs FATE Comparison
UNCY vs FATE Comparison
Compare UNCY & FATE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | UNCY | FATE |
|---|---|---|
| Founded | 2016 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 126.4M | 122.3M |
| IPO Year | 2021 | 2013 |
Fundamental Metrics
Financial Performance| Metric | UNCY | FATE |
|---|---|---|
| Price | $6.25 | $1.04 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 4 | 7 |
| Target Price | ★ $44.50 | $3.92 |
| AVG Volume (30 Days) | 419.9K | ★ 1.6M |
| Earning Date | 11-12-2025 | 03-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $7,137,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $3.71 | $0.66 |
| 52 Week High | $11.00 | $1.94 |
Technical Indicators
Market Signals| Indicator | UNCY | FATE |
|---|---|---|
| Relative Strength Index (RSI) | 55.85 | 48.64 |
| Support Level | $5.65 | $1.02 |
| Resistance Level | $5.95 | $1.09 |
| Average True Range (ATR) | 0.43 | 0.05 |
| MACD | 0.05 | 0.01 |
| Stochastic Oscillator | 70.77 | 46.04 |
Price Performance
Historical ComparisonAbout UNCY Unicycive Therapeutics Inc.
Unicycive Therapeutics Inc is a biotechnology company dedicated to developing treatments for certain medical conditions. It is focusing on kidney diseases. The company's manufactures drug, Renazorb, is a novel phosphate-binding agent being developed for the treatment of hyperphosphatemia. Unicycive's other drug, UNI-494, is a new chemical entity with the issued composition of matter patent protection in late preclinical development for the treatment of acute kidney injury. Company's pipeline comprised of two product candidates: Oxylanthanum Carbonate and UNI-494.
About FATE Fate Therapeutics Inc.
Fate Therapeutics Inc is a clinical-stage biopharmaceutical company based in the United States. It is engaged in the development of programmed cellular immunotherapies for cancer and autoimmune disorders. The company's cell therapy pipeline is comprised of NK- and T-cell immuno-oncology programs, including off-the-shelf engineered product candidates derived from clonal master iPSC lines, and immuno-regulatory programs, including product candidates to prevent life-threatening complications in patients.